307 related articles for article (PubMed ID: 29293244)
1. Cancer immunotherapy.
Bender E
Nature; 2017 Dec; 552(7685):S61. PubMed ID: 29293244
[No Abstract] [Full Text] [Related]
2. A power surge for cancer immunotherapy: antibodies, vaccines, and engineered T cells fuel new optimism.
Nelson B
Cancer Cytopathol; 2014 Jan; 122(1):1-2. PubMed ID: 24424750
[No Abstract] [Full Text] [Related]
3. Safety concerns blight promising cancer therapy.
Ledford H
Nature; 2016 Oct; 538(7624):150-151. PubMed ID: 27734893
[No Abstract] [Full Text] [Related]
4. Cancer Immunotherapy: Theory and Application.
Chen G; Bodogai M; Tamehiro N; Shen C; Dou J
J Immunol Res; 2018; 2018():7502161. PubMed ID: 30035133
[No Abstract] [Full Text] [Related]
5. Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.
Peinert S; Kershaw MH; Prince HM
Immunotherapy; 2009 Nov; 1(6):905-12. PubMed ID: 20635906
[No Abstract] [Full Text] [Related]
6. Attack of the killer clones.
Scudellari M
Nature; 2017 Dec; 552(7685):S64-S66. PubMed ID: 29293233
[No Abstract] [Full Text] [Related]
7. [Perspectives for tumour immunology: antigen-specific immunotherapy of malignant diseases].
Jäger E; Jäger D; Knuth A
Dtsch Med Wochenschr; 2001 Sep; 126(37):1011-6. PubMed ID: 11555776
[No Abstract] [Full Text] [Related]
8. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
Ikeda H
Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.
Seremet T; Brasseur F; Coulie PG
Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282
[TBL] [Abstract][Full Text] [Related]
10. Manufacturing genetically modified T cells for clinical trials.
Gee AP
Cancer Gene Ther; 2015 Mar; 22(2):67-71. PubMed ID: 25633481
[TBL] [Abstract][Full Text] [Related]
11. Cancer vaccines: translation from mice to human clinical trials.
Maeng H; Terabe M; Berzofsky JA
Curr Opin Immunol; 2018 Apr; 51():111-122. PubMed ID: 29554495
[TBL] [Abstract][Full Text] [Related]
12. When transgenes shape immunity: cancer immune-gene therapy.
Bonini C; Parmiani G
J Gene Med; 2012 Jun; 14(6):384-5. PubMed ID: 22736622
[No Abstract] [Full Text] [Related]
13. Therapeutic cancer vaccines: From initial findings to prospects.
Song Q; Zhang CD; Wu XH
Immunol Lett; 2018 Apr; 196():11-21. PubMed ID: 29407608
[TBL] [Abstract][Full Text] [Related]
14. mRNA Cancer Vaccines.
Fiedler K; Lazzaro S; Lutz J; Rauch S; Heidenreich R
Recent Results Cancer Res; 2016; 209():61-85. PubMed ID: 28101688
[TBL] [Abstract][Full Text] [Related]
15. Human Tumor Antigens and Cancer Immunotherapy.
Vigneron N
Biomed Res Int; 2015; 2015():948501. PubMed ID: 26161423
[TBL] [Abstract][Full Text] [Related]
16. Armed T cells with CAR for cancer immunotherapy.
Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):331-2. PubMed ID: 27080712
[No Abstract] [Full Text] [Related]
17. Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy.
Pedersen SR; Sørensen MR; Buus S; Christensen JP; Thomsen AR
J Immunol; 2013 Oct; 191(7):3955-67. PubMed ID: 24018273
[TBL] [Abstract][Full Text] [Related]
18. Antigen choice in adoptive T-cell therapy of cancer.
Offringa R
Curr Opin Immunol; 2009 Apr; 21(2):190-9. PubMed ID: 19297140
[TBL] [Abstract][Full Text] [Related]
19. Future of immunotherapy drug combinations and biomarkers.
Schmidt C
J Natl Cancer Inst; 2012 Mar; 104(6):434-9. PubMed ID: 22402694
[No Abstract] [Full Text] [Related]
20. Glioma antigen.
Toda M
Adv Exp Med Biol; 2012; 746():77-84. PubMed ID: 22639160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
